Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06112509
Other study ID # 2023/XXXX
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 1, 2024
Est. completion date November 1, 2024

Study information

Verified date October 2023
Source Centre Hospitalier Universitaire de Besancon
Contact Mylene ABISSE, MD
Phone +33381218988
Email mabisse@chu-besancon.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the vestibular effects of gamma-knife radiosurgery, as part of the treatment of vestibular schwannoma.


Description:

Vestibular schwannoma is a benign tumor located on the vestibulocochlear nerve. It represents 6 to 8% of intracranial tumors, 80% of ponto-cerebral angle tumors and its frequency is 13 cases per million inhabitants per year. The main symptoms related to the development of vestibular schwannoma are unilateral deafness of perception, unilateral tinnitus, unilateral vestibular deficit vertigo, facial paralysis. Management is divided into 3 options: monitoring, surgery and gamma-knife radiosurgery. This study will focus on gamma-knife radiosurgery. The objective of this treatment is to stabilize the evolution of schwannoma. This study aims to describe the vestibular effects of radiosurgery.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date November 1, 2024
Est. primary completion date November 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria : - Men and women aged 18 to 90 included - Subject who benefited from gamma-knife radiosurgery as part of the treatment of vestibular schwannoma - Non-opposition of the subject to participate in the study - Affiliation to a French social security scheme or beneficiary of such a scheme Exclusion Criteria : - Subject with another vestibular pathology - Subject who did not benefit from a vestibular assessment before treatment with gamma-knife radiosurgery - Legal incapacity or limited legal capacity - Subject unlikely to cooperate in the study and/or weak cooperation anticipated by the investigator - Subject without health insurance - Subject being in the period of exclusion from another study or provided for by the "national volunteer file".

Study Design


Intervention

Other:
Vestibular exam
Interrogation, videonystagmoscopy, videonystagmography, video-head-impulse-test

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Besancon

Outcome

Type Measure Description Time frame Safety issue
Primary Description of vestibular function with videonystagmography before gamma-knife radiosurgery, as part of the treatment of vestibular schwannoma. Videonystagmography: Results of caloric tests = Intervestibular deficit (in percentage) 1 month before gamma-knife radiosurgery
Primary Description of vestibular function with vidéonystagmoscopy before gamma-knife radiosurgery, as part of the treatment of vestibular schwannoma. Videonystagmography: Results of caloric tests = Intervestibular deficit (in percentage) After gamma-knife radiosurgery at 6 month or 12 month or 18 month or 2 years or 3 years depending on the history of the treatment
Secondary Description of vestibular symptoms before gamma-knife radiosurgery as part of the treatment of vestibular schwannoma. Dizziness Handicap Inventoryquestionnaire (DHI questionnaire) 1 month before gamma-knife radiosurgery
Secondary Description of vestibular symptoms after gamma-knife radiosurgery as part of the treatment of vestibular schwannoma. Dizziness Handicap Inventoryquestionnaire (DHI questionnaire) After gamma-knife radiosurgery at 6 month or 12 month or 18 month or 2 years or 3 years depending on the history of the treatment
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Active, not recruiting NCT00973739 - Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Phase 2
Completed NCT04351373 - Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 Phase 2
Active, not recruiting NCT01449604 - Stereotactic Radiation in Vestibular Schwannoma Phase 3
Completed NCT01207687 - Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Phase 2
Not yet recruiting NCT05567341 - Remote Ischemic Preconditioning in Vestibular Schwannoma Surgery N/A
Completed NCT02249572 - Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. N/A
Terminated NCT05116878 - Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma N/A
Suspended NCT03095248 - Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Phase 2
Recruiting NCT04801953 - Nimodipine in Vestibular Schwanommas Phase 2
Recruiting NCT03745560 - Intraoperative EABR for Decision Making
Recruiting NCT04859335 - Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma N/A
Recruiting NCT04128345 - Novel Multimodality Imaging for Navigation in Skull Base Surgery
Active, not recruiting NCT01199978 - Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Phase 2
Recruiting NCT04057976 - Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas N/A
Completed NCT00863122 - Concentration and Activity of Lapatinib in Vestibular Schwannomas Early Phase 1
Recruiting NCT04374305 - Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Phase 2
Recruiting NCT03079999 - Study of Aspirin in Patients With Vestibular Schwannoma Phase 2
Recruiting NCT05786144 - Vestibular Schwannoma Organoids
Recruiting NCT03593577 - Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI